S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Cigarette smoking is of great public health importance and is the single most important preventable cause of morbidity, mortality and excess health care costs in the United States. After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 21%. Currently available treatments among adults are not efficacious for all tobacco users. New pharmacologic agents thus need to be continually developed and tested.
The release of dopamine in the nucleus accumbens is one of the key components of the pleasurable and rewarding effects of nicotine. Drugs that increase monoamine neurotransmitter availability (particularly dopamine and norepinephrine) are likely to increase the reward function and thus ameliorate withdrawal symptoms. S-Adenosyl-L-Methionine (SAMe), the primary methyl donor for the central nervous system (CNS), donates methyl groups towards presynaptic synthesis of CNS monoamine neurotransmitters. By facilitating the synthesis of dopamine and norepinephrine in the brain, SAMe is likely to ameliorate the symptoms of nicotine withdrawal, thus improving tobacco abstinence rates in smokers who are trying to stop smoking. SAMe is well tolerated and is available over-the-counter.
To date, no prospective clinical trial evaluating the efficacy of SAMe for the treatment of tobacco dependence has been published. We propose to evaluate the efficacy of SAMe for increasing smoking abstinence and decreasing nicotine withdrawal symptoms in a randomized, blinded, placebo-controlled, three-arm, parallel-group, dose-ranging phase II clinical trial. Participants (N=120) will be randomly assigned to one of the three groups, and will receive an 8-week course of SAMe 800-mg per day, 1600-mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism, if the results appear promising.
| Condition | Intervention | Phase |
|---|---|---|
|
Tobacco Dependence |
Drug: S-Adenosyl-L-Methionine Other: placebo |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence |
- 7-day Point Prevalence Smoking Abstinence at End of Treatment (Week 8) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]7-day point prevalence smoking abstinence biochemically confirmed (expired carbon monoxide <8ppm)
| Enrollment: | 150 |
| Study Start Date: | September 2008 |
| Study Completion Date: | June 2010 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: SAMe 800
Each subject randomized to this arm will take a 400 mg pill of SAMe and one matching placebo pill in the AM and again in the PM
|
Drug: S-Adenosyl-L-Methionine
800 mg dose per day for 8 weeks
Other Name: SAMe
|
|
Active Comparator: SAMe 1600
Each person randomized to this arm will take 2 400 mg pills of SAMe in the AM and again in the PM
|
Drug: S-Adenosyl-L-Methionine
1600 mg per day for 8 weeks
Other Name: SAMe
|
|
Placebo Comparator: Placebo
Each subject randomized to this arm will take 2 placebo pills in the AM and again in the PM
|
Other: placebo
4 pills (2 in the AM and 2 in the PM) of placebos for 8 weeks
Other Name: sugar pill
|
Detailed Description:
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Is at least 18 years of age;
- Has smoked more than 10 cigarettes/day for ≥6 months;
- Is willing to make a quit attempt;
- Is able to participate fully in all aspects of the study;
- Has been provided with, understand, and have signed the informed consent.
- Is in good health as determined by the physician investigator.
Exclusion Criteria:
- Is clinically significant levels of current depression as assessed by CESD (Score >16) and determined by the physician; or have a life-time diagnosis of bipolar disorder, schizophrenia or dementia as determined by physician investigator;
- Has an unstable medical condition.
- Is using other tobacco product and the primary use is NOT cigarettes.
- Is currently (within the past 30-days) using antipsychotics or antidepressants;
- Is currently (within the past 30-days) using any treatments for tobacco dependence (i.e., behavioral therapy, nicotine replacement therapy, bupropion SR, clonidine, or nortriptyline);
- Is currently using another investigational drug at the time of study enrollment;
- Is currently (within the past 30 days) using an herbal product or dietary supplement for tobacco abstinence;
- Has recent history (in the past 3-months) of alcohol abuse or dependence as assessed by the CAGE questionnaire and study investigators;
- Has a recent history of drug abuse as assessed by physician interview;
- Is pregnant, lactating, or of child bearing potential, likely to become pregnant during the medication phase and not willing to use a reliable form of contraception. Reliable forms of contraception include diaphragm or condom (with spermicidal), injections, intrauterine device [IUD], surgical sterilization and abstinence;
- Is a history of any major cardiovascular events in the past 3-months including unstable angina, acute MI or coronary angioplasty;
- Has clinically significant acute or chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, respiratory or metabolic disease;
- Is currently on medications interacting with SAMe, including but not limited to, antidepressants, MAO inhibitors, levodopa, meperidine, dextromethorphan, pentazocine and tramadol;
- Has another household member or relative participating in the study;
- Has known allergy to SAMe.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00722124
| United States, Minnesota | |
| Mayo Clinic | |
| Rochester, Minnesota, United States, 55905 | |
| United States, Wisconsin | |
| Franciscan Skemp HealthCare | |
| La Crosse, Wisconsin, United States, 54601 | |
| Principal Investigator: | Amit Sood, M.D. | Mayo Clinic |
More Information
Additional Information:
| Responsible Party: | Amit Sood, M.D., Mayo Clinic |
| ClinicalTrials.gov Identifier: | NCT00722124 History of Changes |
| Other Study ID Numbers: | 07-006365 07-006604 |
| Study First Received: | July 23, 2008 |
| Results First Received: | August 5, 2011 |
| Last Updated: | August 5, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Mayo Clinic:
|
tobacco use cigarettes smokers |
Additional relevant MeSH terms:
|
Tobacco Use Disorder Substance-Related Disorders Chemically-Induced Disorders Mental Disorders |
ClinicalTrials.gov processed this record on September 23, 2016